APC Share Price

Open 0.07 Change Price %
High 0.07 1 Day 0.00 0.00
Low 0.07 1 Week 0.00 0.00
Close 0.07 1 Month 0.01 16.67
Volume 20000 1 Year 0.01 16.67
52 Week High 0.10
52 Week Low 0.04
APC Important Levels
Resistance 2 0.07
Resistance 1 0.07
Pivot 0.07
Support 1 0.07
Support 2 0.07
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
DYA 0.83 -11.70%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
KWF 1.69 238.00%
BVQ 0.02 100.00%
AZU 0.02 100.00%
AZU 0.02 100.00%
DDX 0.50 100.00%
ADE 0.02 100.00%
RDM 0.21 90.91%
RDM 0.21 90.91%
WTR 0.21 50.00%
WTR 0.21 50.00%
More..
CVE Canada Top Losers Stocks
LTX 0.00 -100.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
VGD 0.02 -33.33%
More..

Advanced Proteome Therpt (CVE: APC)

APC Technical Analysis 4
As on 27th Mar 2017 APC Share Price closed @ 0.07 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.05 & Buy for SHORT-TERM with Stoploss of 0.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
APC Target for March
1st Target up-side 0.08
2nd Target up-side 0.1
3rd Target up-side 0.11
1st Target down-side 0.04
2nd Target down-side 0.02
3rd Target down-side 0.01
APC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.advancedproteome.com
APC Address
APC
BioSquare
Suite 113
Boston, MA 02118
United States
Phone: 617-638-0340
Fax: 617-638-0341
Interactive Technical Analysis Chart Advanced Proteome Therpt ( APC CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Advanced Proteome Therpt
APC Business Profile
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. It focuses on the development of a patent-pending technology that combines multiple anti-cancer therapies in a single agent to directly target cancer tumors. The company is headquartered in Boston, Massachusetts.